PE20221004A1 - Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados - Google Patents
Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionadosInfo
- Publication number
- PE20221004A1 PE20221004A1 PE2021002191A PE2021002191A PE20221004A1 PE 20221004 A1 PE20221004 A1 PE 20221004A1 PE 2021002191 A PE2021002191 A PE 2021002191A PE 2021002191 A PE2021002191 A PE 2021002191A PE 20221004 A1 PE20221004 A1 PE 20221004A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr2
- cdr1
- cdr3
- antibody
- comprises seq
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 4
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 abstract 2
- 108010000499 Thromboplastin Proteins 0.000 abstract 2
- 102000002262 Thromboplastin Human genes 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
El presente documento define un conjugado anticuerpo y farmaco que comprende: a. una proteina de union al antigeno (Ab) que se une al domino extracelular del factor tisular (TF) humano (SEQ ID n.º: 810), donde el Ab comprende una VHCDR1, una VH-CDR2, una VH-CDR3, una VL-CDR1, una VL-CDR2 y una VLCDR3, donde i. la VH-CDR1 comprende la SEQ ID n.°: 872, la VH-CDR2 comprende la SEQ ID n.°: 873, la VH-CDR3 comprende la SEQ ID n.°: 874, la VL-CDR1 comprende la SEQ ID n.°: 875, la VL-CDR2 comprende la SEQ ID n.°: 876 y la VL-CDR3 comprende la SEQ ID n.°: 877, ii. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A3, iii. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A, iv. la VH-CDR1, la VH-CDR2, la VH-CDR3, la VL-CDR1, la VL-CDR2 y la VLCDR3 son del anticuerpo designado 25A5, v. VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 y VL-CDR3 son del anticuerpo designado 25A5-T o vi. VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 y VL-CDR3 son del anticuerpo designado 25G1; y b. una o mas fracciones de toxinas y conectores representados por la Formula IV, en donde; X es -C(O)NHCH(CH2(R2 ))-+ , donde y + representan los respectivos puntos de union, como se indica en la Formula IV, o X esta ausente; L es un conector; ! representa el punto de union de L con el Ab, donde L se une al Ab mediante un enlace covalente; R1 se selecciona del grupo que consiste en ( ) donde # y % representan los respectivos puntos de union, como se indica en la Formula IV y R2 es fenilo. En el presente documento se proporcionan anticuerpos que se unen especificamente al factor tisular (TF) humano, conjugados de anticuerposfarmacos (ADC) antiTF y composiciones que comprenden a los anticuerpos o ADC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962870644P | 2019-07-03 | 2019-07-03 | |
PCT/US2020/040711 WO2021003399A1 (en) | 2019-07-03 | 2020-07-02 | Anti-tissue factor antibody-drug conjugates and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221004A1 true PE20221004A1 (es) | 2022-06-15 |
Family
ID=74100836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021002191A PE20221004A1 (es) | 2019-07-03 | 2020-07-02 | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220257789A1 (es) |
EP (1) | EP3994150A4 (es) |
JP (1) | JP2022538908A (es) |
KR (1) | KR20220029724A (es) |
CN (1) | CN114222752A (es) |
AR (1) | AR119346A1 (es) |
AU (1) | AU2020299398A1 (es) |
BR (1) | BR112021025720A2 (es) |
CA (1) | CA3141428A1 (es) |
CL (1) | CL2021003414A1 (es) |
CO (1) | CO2022001083A2 (es) |
CR (1) | CR20220047A (es) |
DO (1) | DOP2021000268A (es) |
EA (1) | EA202193309A1 (es) |
EC (1) | ECSP22007981A (es) |
IL (1) | IL289138A (es) |
MX (1) | MX2021015974A (es) |
PE (1) | PE20221004A1 (es) |
TW (1) | TW202116357A (es) |
WO (1) | WO2021003399A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023137399A2 (en) * | 2022-01-12 | 2023-07-20 | Iconic Therapeutics Llc | Inflammatory disease treatment using anti-tissue factor antibodies |
WO2023160651A1 (zh) * | 2022-02-24 | 2023-08-31 | 苏州信诺维医药科技股份有限公司 | 一种抗体及其药物偶联物和用途 |
WO2023172951A1 (en) * | 2022-03-09 | 2023-09-14 | Exelixis, Inc. | Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates |
WO2023196869A1 (en) * | 2022-04-05 | 2023-10-12 | Atreca, Inc. | Epha2 antibodies |
CN116143929B (zh) * | 2023-02-03 | 2023-08-01 | 北京基科晟斯医药科技有限公司 | 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2802782C (en) * | 2010-06-15 | 2018-03-13 | Genmab A/S | Human antibody drug conjugates against tissue factor |
HUE057768T2 (hu) * | 2014-09-17 | 2022-06-28 | Zymeworks Inc | Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei |
HRP20211980T1 (hr) * | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
JP7437301B2 (ja) * | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-h4抗体及びその使用方法 |
BR112020008593A2 (pt) * | 2017-11-02 | 2020-10-20 | Genmab A/S | método de tratamento de câncer cervical em um indivíduo |
CA3083345A1 (en) * | 2017-11-27 | 2019-05-31 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
JP2021509823A (ja) * | 2018-01-04 | 2021-04-08 | アイコニック セラピューティクス インコーポレイテッド | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
-
2020
- 2020-07-02 EP EP20835557.8A patent/EP3994150A4/en active Pending
- 2020-07-02 MX MX2021015974A patent/MX2021015974A/es unknown
- 2020-07-02 CA CA3141428A patent/CA3141428A1/en active Pending
- 2020-07-02 AU AU2020299398A patent/AU2020299398A1/en active Pending
- 2020-07-02 BR BR112021025720A patent/BR112021025720A2/pt unknown
- 2020-07-02 JP JP2022500008A patent/JP2022538908A/ja active Pending
- 2020-07-02 US US17/624,541 patent/US20220257789A1/en active Pending
- 2020-07-02 EA EA202193309A patent/EA202193309A1/ru unknown
- 2020-07-02 PE PE2021002191A patent/PE20221004A1/es unknown
- 2020-07-02 CR CR20220047A patent/CR20220047A/es unknown
- 2020-07-02 KR KR1020227003549A patent/KR20220029724A/ko unknown
- 2020-07-02 WO PCT/US2020/040711 patent/WO2021003399A1/en active Application Filing
- 2020-07-02 CN CN202080054283.1A patent/CN114222752A/zh active Pending
- 2020-07-03 TW TW109122635A patent/TW202116357A/zh unknown
- 2020-07-03 AR ARP200101887A patent/AR119346A1/es unknown
-
2021
- 2021-12-19 IL IL289138A patent/IL289138A/en unknown
- 2021-12-20 CL CL2021003414A patent/CL2021003414A1/es unknown
- 2021-12-20 DO DO2021000268A patent/DOP2021000268A/es unknown
-
2022
- 2022-02-01 CO CONC2022/0001083A patent/CO2022001083A2/es unknown
- 2022-02-01 EC ECSENADI20227981A patent/ECSP22007981A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR119346A1 (es) | 2021-12-09 |
KR20220029724A (ko) | 2022-03-08 |
CA3141428A1 (en) | 2021-01-07 |
EP3994150A1 (en) | 2022-05-11 |
TW202116357A (zh) | 2021-05-01 |
IL289138A (en) | 2022-02-01 |
JP2022538908A (ja) | 2022-09-06 |
CO2022001083A2 (es) | 2022-05-20 |
CN114222752A (zh) | 2022-03-22 |
EA202193309A1 (ru) | 2022-03-28 |
BR112021025720A2 (pt) | 2022-06-21 |
WO2021003399A1 (en) | 2021-01-07 |
AU2020299398A1 (en) | 2022-02-24 |
CR20220047A (es) | 2022-06-23 |
CL2021003414A1 (es) | 2022-09-09 |
US20220257789A1 (en) | 2022-08-18 |
MX2021015974A (es) | 2022-04-26 |
DOP2021000268A (es) | 2022-08-15 |
ECSP22007981A (es) | 2022-05-31 |
EP3994150A4 (en) | 2023-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221004A1 (es) | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados | |
US11912763B2 (en) | Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof | |
JP6727379B2 (ja) | Her2を標的とする二重特異性抗原結合性コンストラクト | |
CA2964830C (en) | Anti-tim3 antibodies and methods of use | |
ES2784685T3 (es) | Productos conjugados de anticuerpo-fármaco específicos de AXL para el tratamiento del cáncer | |
CN103889452B (zh) | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 | |
PE20091112A1 (es) | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo | |
ES2854708T3 (es) | Anticuerpos dirigidos contra la cadena alfa del receptor de IL7: su uso para la preparación de fármacos candidatos | |
CN104411725B (zh) | 抗生物素抗体及使用方法 | |
DK3102606T3 (en) | ANTIBODY MEDICINAL CONJUGATES AND IMMUNTOXINES | |
CN108137702A (zh) | 抗siglec-7抗体及其使用方法 | |
CN107074948A (zh) | 结合axl的抗体 | |
CN106255705A (zh) | 结合HER3β‑发夹和HER2域II的HER3/HER2双特异性抗体 | |
ES2633297T3 (es) | Anticuerpos monoclonales al factor básico de crecimiento de fibroblastos | |
BRPI0719762B8 (pt) | anticorpo humano isolado, composição, polinucleotídeo isolado, vetor de expressão, microrganismo isolado, método para fabricação de um anticorpo, e, uso de um anticorpo | |
CN105949313A (zh) | 抗体Fc变体 | |
PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
CO6290705A2 (es) | Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos | |
PE20090368A1 (es) | Anticuerpos anti-igf | |
JP6872482B2 (ja) | Her2を標的とする二重特異性抗原結合性構築物の使用方法 | |
PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
CN104394886B (zh) | 抗茶碱抗体及使用方法 | |
CN104520328A (zh) | 抗锯齿蛋白抗体及使用方法 | |
JP2023505318A (ja) | ヒト化cldn18.2抗体 |